IMMUNOTHERAPY BRIDGE
December 4th-5th, 2019
Royal Continental Hotel, Naples, Italy



Presidents


Paolo A. Ascierto

Paolo A. Ascierto
Director, Medical Oncology, Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, National Cancer Institute Fondazione "G. Pascale", Naples, Italy



Lisa H. Butterfield

Lisa H. Butterfield
Research Center Vice President, Parker Institute for Cancer Immunotherapy and Adjunct Professor of Microbiology and Immunology, University of California, San Francisco, California, US



Igor Puzanov

Igor Puzanov
Director, Early Phase Clinical Trials Program, Chief of Melanoma, Co-Leader, CCSG Experimental Therapeutics Program, Professor of Oncology, Department of Medicine, Roswell Park Comprehensive Cancer Center, Developmental Therapeutics, Buffalo, New York, USA





Scientific Board


Sanjiv Agarwala

Sanjiv Agarwala
Professor & Chief, Haematology & Oncology, St Luke's University Hospital and Temple University, Bethlehem, Pennsylvania, US



Paolo A. Ascierto

Paolo A. Ascierto
Director, Medical Oncology, Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, National Cancer Institute Fondazione "G. Pascale", Naples, Italy



Carlo Bifulco

Carlo Bifulco
Medical Director of Oncological Molecular Pathology and Pathology Informatics, Providence Oregon Regional Laboratory and Earle A. Chiles Research Institute, Portland, Oregon, US



Lisa H. Butterfield

Lisa H. Butterfield
Research Center Vice President, Parker Institute for Cancer Immunotherapy and Adjunct Professor of Microbiology and Immunology, University of California, San Francisco, California, US



Corrado Caracò

Corrado Caracò
Director of Department Melanoma, Soft Tissue, Muscle-Skeletal and Head-Neck, National Cancer Institute "Fondazione G. Pascale", Naples, Italy



Sandra Demaria

Sandra Demaria
Professor of Pathology and Laboratory Medicine, Professor of Radiation Oncology and Adjunct Professor at Department of Pathology, Weill Cornell Medical College and NYU School of Medicine, New York City, New York, US


Reinhard Dummer

Reinhard Dummer
Professor of Dermatology, University of Zurich Hospital, Department of Dermatology, Zurich, Switzerland



Bernard A. Fox

Bernard A. Fox
Chief of Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute at Providence Cancer Center, Portland, Oregon, US



Jerome Galon

Jerome Galon
Research Director, National Institute of Health and Medical Research (INSERM), Paris, France




Claus Garbe

Claus Garbe
University Professor of Dermatology, Division of Dermatologic Oncology Department of Dermatology, Eberhard- Karls University Tuebingen, Germany



Omid Hamid

Omid Hamid
Chief of Research/ Immuno-Oncology and Co-Director, Cutaneous Malignancy Program, The Angeles Clinic and Research Institute, Los Angeles, California, USA



Giuseppe Masucci

Giuseppe Masucci
Professor, Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden




Giuseppe Palmieri

Giuseppe Palmieri
President Italian Melanoma Intergroup (IMI), Head of Unit of Cancer Genetics, Institute of Biomolecular Chemistry (ICB), National Research Council (CNR), Sassari, Italy



Michael Postow

Michael Postow
Memorial Sloane Kettering Cancer Center, New York City, New York, USA




Igor Puzanov

Igor Puzanov
Director, Early Phase Clinical Trials Program, Chief of Melanoma, Co-Leader, CCSG Experimental Therapeutics Program, Professor of Oncology, Department of Medicine, Roswell Park Comprehensive Cancer Center, Developmental Therapeutics, Buffalo, New York, USA


Magdalena Thurin

Magdalena Thurin
Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland, USA



Tara Withington

Tara Withington
Executive Director of Society of Immunotherapy for Cancer (SITC), Milwaukee, Wisconsin, USA






 


For information please contact info@melanomabridge.org